Cilostazol effectiveness in reducing drug-coated stent restenosis in the superficial femoral artery: The ZERO study.
<h4>Purpose</h4>Drug-eluting stents (DESs) play an important role in endovascular therapy (EVT) for femoropopliteal (FP) lesions. Cilostazol improves patency after bare-metal nitinol stent (BNS) implantation for femoropopliteal lesions. This study aimed to establish whether cilostazol is...
Main Authors: | Takashi Miura, Yusuke Miyashita, Koji Hozawa, Tatsuki Doijiri, Tamon Kato, Naoki Hayakawa, Naoto Hashizume, Masatsugu Nakano, Uichi Ikeda, Koichiro Kuwahara, ZERO Investigators |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2022-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0270992 |
Similar Items
-
Directional Atherectomy for Treating In-Stent Restenosis of the Superficial Femoral Artery
by: Sungsin Cho, et al.
Published: (2020-09-01) -
Prognostic Factors for Restenosis of Superficial Femoral Artery after Endovascular Treatment
by: Vinko Boc, et al.
Published: (2023-10-01) -
The study on the risk factors of restenosis after superficial femoral artery stenting
by: Xixiang Gao, et al.
Published: (2023-01-01) -
POLYCYTHEMIA VERA IDENTIFIED IN A PATIENT WITH RESTENOSIS OF THE SUPERFICIAL FEMORAL ARTERY. CLINICAL CASE AND REVIEW OF THE LITERATURE
by: G. Sh. Safuanova, et al.
Published: (2017-05-01) -
A better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine
by: Ikushima I, et al.
Published: (2011-06-01)